Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

18 Jun 2012

BEAMing DNA blood testing technology detects drug resistance in colorectal cancer patients early

Two studies published back-to-back in last week's Nature applied DNA blood testing using the BEAMing technology to detect drug resistance mediated by KRAS mutations in colorectal cancer patients months before treatment failure was observed.

18 Jun 2012

Theraclone Sciences commences TCN-202 Phase 1 trial in CMV infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-202, a broadly protective, fully human monoclonal antibody in development for the treatment of human cytomegalovirus (CMV) infection.

15 Jun 2012

Laparoscopy technique lights up invisible metastases

Fluorescence laparoscopy could be the way forward for cancer surgery and staging, say researchers writing in the Archives of Surgery.

14 Jun 2012

Cancers often recur after treatment with single drugs that “target” tumor cells’ genetic pathways

Targeted cancer cell therapies using man-made proteins dramatically shrink many tumors in the first few months of treatment, but new research from Johns Hopkins scientists finds why the cells all too often become resistant, the treatment stops working, and the disease returns.

14 Jun 2012

Acorda commences AMPYRA clinical study for post-stoke deficits

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in a proof-of-concept study exploring the use of AMPYRA(dalfampridine) Extended Release Tablets, 10 mg in treating patients who have post-stroke deficits.

13 Jun 2012

Igenica raises $33M in Series C round of funding

Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.

12 Jun 2012

Genzyme files LEMTRADA sBLA and MAA with FDA, EMA for treatment of RMS

Genzyme, a Sanofi company, today announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).

12 Jun 2012

Genentech receives FDA approval for Perjeta to treat HER2-positive metastatic breast cancer

The U.S. Food and Drug Administration today approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage (metastatic) breast cancer.

10 Jun 2012

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

Patients with active psoriatic arthritis receiving the interleukin (IL)-12/23 inhibitor STELARA (ustekinumab) experienced significant improvements in signs and symptoms of the disease, according to new findings presented today from a Janssen Research & Development, LLC, (Janssen)-sponsored investigational study.

6 Jun 2012

BioInvent, ThromboGenics to regain global rights to TB-403 from Roche

ThromboGenics NV and co-development partner BioInvent International announce today that they will regain global rights to TB-403 from Roche.

6 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor initiating cells, today highlighted new data presented this afternoon in a poster discussion session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

Personalized medicine and the Human Genome Project

It’s nearly a decade since the completion of the Human Genome Project, (1) which aimed to sequence the complete human genome.

1 Jun 2012

Taiho to initiate TAS-102 Phase III trial in colorectal cancer

Taiho Pharmaceutical Co., Ltd. announced on May 31 that a global Phase III clinical trial (RECOURSE) for the novel combination antimetabolite TAS-102 will start in June this year.

31 May 2012